Evidence map›Paper›PMID 36693186›Full record

ArticleClinical cancer research : an official journal of the American Association for Cancer Research2023

Pathogenic Variants in Adult-Onset Cancer Predisposition Genes in Pediatric Cancer: Prevalence and Impact on Tumor Molecular Features and Clinical Management.

Rose B McGee, Ninad Oak, Lynn Harrison, Ke Xu, Regina Nuccio, Alise K Blake, Roya Mostafavi, Sara Lewis, Leslie M Taylor, Manish Kubal and 5 more

Open access · greenAbstract read
In one paragraph

Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
3.3field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Double Heterozygous Pathogenic Variants inInternational journal of molecular sciences · 2024
    Article
  8. Adult-Onset Cancer Predisposition Syndromes in Children and Adolescents-To Test or not to Test?Clinical cancer research : an official journal of the American Association for Cancer Research · 2024
    Article
  9. Article
  10. Reply to Li and Colleagues.Journal of the National Cancer Institute · 2023
    Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 1 institution in 1 country.

Rose B McGee *Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee.ORCID 0000-0001-7392-6515
Ninad Oak *Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee.ORCID 0000-0002-9806-0217
Lynn HarrisonDepartment of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee.ORCID 0000-0001-7595-080X
Ke XuCenter for Applied Bioinformatics, St. Jude Children's Research Hospital, Memphis, Tennessee.ORCID 0000-0002-8130-1109
Regina NuccioDepartment of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee.ORCID 0000-0002-6478-7020
Alise K BlakeDepartment of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee.ORCID 0000-0002-1336-7106
Roya MostafaviDepartment of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee.ORCID 0000-0002-6606-2920
Sara LewisDepartment of Hematology, St. Jude Children's Research Hospital, Memphis, Tennessee.ORCID 0000-0003-0364-375X
Leslie M TaylorDepartment of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee.ORCID 0000-0002-6718-4559
Manish KubalDepartment of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee.ORCID 0000-0002-4088-3878
Annastasia OumaDepartment of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee.ORCID 0000-0002-4864-8127
Stacy J Hines-DowellDepartment of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee.ORCID 0000-0003-0527-8418
Cheng ChengDepartment of Biostatistics, St. Jude Children's Research Hospital, Memphis, Tennessee.ORCID 0000-0002-0977-0138
Larissa V FurtadoDepartment of Pathology, St. Jude Children's Research Hospital, Memphis, Tennessee.ORCID 0000-0001-7784-9502
Kim E NicholsDepartment of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee.ORCID 0000-0002-5581-6555
St. Jude Children's Research Hospital · US

Funding

Pathogenesis of ETV6-Related Acute Lymphoblastic LeukemiaR01CA241452 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI NICHOLS, KIM ERIKA · 2020 to 2025
$2.6M
NCI NIH HHS R01 CA241452
6 · The paper itself

Abstract

purposeClinical genomic sequencing of pediatric tumors is increasingly uncovering pathogenic variants in adult-onset cancer predisposition genes (aoCPG). Nevertheless, it remains poorly understood how often aoCPG variants are of germline origin and whether they influence tumor molecular profiles and/or clinical care. In this study, we examined the prevalence, spectrum, and impacts of aoCPG variants on tumor genomic features and patient management at our institution. EXPERIMENTAL

designThis is a retrospective study of 1,018 children with cancer who underwent clinical genomic sequencing of their tumors. Tumor genomic data were queried for pathogenic variants affecting 24 preselected aoCPGs. Available tumor whole-genome sequencing (WGS) data were evaluated for second hit mutations, loss of heterozygosity (LOH), DNA mutational signatures, and homologous recombination deficiency (HRD). Patients whose tumors harbored one or more pathogenic aoCPG variants underwent subsequent germline testing based on hereditary cancer evaluation and family or provider preference.

resultsThirty-three patients (3%) had tumors harboring pathogenic variants affecting one or more aoCPGs. Among 21 tumors with sufficient WGS sequencing data, six (29%) harbored a second hit or LOH affecting the remaining aoCPG allele with four of these six tumors (67%) also exhibiting a DNA mutational signature consistent with the altered aoCPG. Two additional tumors demonstrated HRD, of uncertain relation to the identified aoCPG variant. Twenty-one of 26 patients (81%) completing germline testing were positive for the aoCPG variant in the germline. All germline-positive patients were counseled regarding future cancer risks, surveillance, and risk-reducing measures. No patients had immediate cancer therapy changed due to aoCPG data.

conclusionsAoCPG variants are rare in pediatric tumors; however, many originate in the germline. Almost one third of tumor aoCPG variants examined exhibited a second hit and/or conferred an abnormal DNA mutational profile suggesting a role in tumor formation. aoCPG information aids in cancer risk prediction but is not commonly used to alter the treatment of pediatric cancers.

Indexed as

Genetic Predisposition to DiseaseNeoplasmsAdultChildGerm-Line MutationHumansPrevalenceRetrospective StudiesWhole Genome Sequencing

Identifiers

PMID36693186
PMCPMC10642481
OpenAlexW4317864616

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.